The device industry and other Medicare stakeholders are generally supportive of CMS' recent move to publicize topics it is considering for future national coverage determinations, though some worry that the agency will use the process to limit patient access to technologies
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.
Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.
